Chantel Charpentier
Family · Thibodaux, LANPI 1821086133
Payments from drug & device makers
Across 325 payments — averaging $18.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Novo Nordisk$914
- AbbVie$832
- AstraZeneca$563
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$368
- Bayer$238
- plus $2K from 25 others
What the payments were for
- Food & beverage$5,71697%
- Education$1903%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 70 | $1,139 |
| Novo Nordisk | 46 | $914 |
| AbbVie | 62 | $832 |
| AstraZeneca | 16 | $563 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 25 | $368 |
| Bayer | 14 | $238 |
| Astellas Pharma US Inc | 5 | $232 |
| Boehringer Ingelheim | 15 | $217 |
| Pfizer | 10 | $180 |
| Lilly USA, LLC | 8 | $151 |
| Otsuka America Pharmaceutical, Inc. | 7 | $133 |
| Teva Pharmaceuticals USA, Inc. | 2 | $133 |
| Merck | 6 | $91 |
| Alkermes, Inc. | 5 | $89 |
| Sanofi-aventis U.S. LLC | 4 | $84 |
| Vanda Pharmaceuticals Inc. | 3 | $81 |
| Amgen | 4 | $71 |
| Dexcom, Inc. | 3 | $68 |
| Supernus Pharmaceuticals, Inc. | 4 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| Mylan Specialty L.p. | 2 | $32 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Paratek Pharmaceuticals, Inc. | 2 | $28 |
| Sunovion Pharmaceuticals Inc. | 2 | $28 |
| Novartis | 1 | $20 |
| Lundbeck LLC | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Shield Therapeutics Inc | 1 | $16 |
| Abbott | 1 | $16 |
| Exact Sciences | 1 | $15 |
| Sun Pharmaceutical Industries Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,906 in reported general payments places this provider in the 90th percentile of 3,610 family providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 149 | $149,405 |
| MounjaroTirzepatide | 67 | $82,754 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 109 | $77,569 |
| JardianceEmpagliflozin | 62 | $48,165 |
| RybelsusSemaglutide | 38 | $42,968 |
| TradjentaLinagliptin | 58 | $42,301 |
| JanuviaSitagliptin Phosphate | 25 | $24,096 |
| UbrelvyUbrogepant | 14 | $23,350 |
| FarxigaDapagliflozin Propanediol | 23 | $22,281 |
| EliquisApixaban | 21 | $20,831 |
| LinzessLinaclotide | 27 | $17,990 |
| SymbicortBudesonide/Formoterol Fumarate | 66 | $17,229 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 31 | $16,562 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 27 | $15,601 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $14,053 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $914 | $192,373187 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $1,139 | $107,158162 claims |
| Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat | $217 | $106,068147 claims |
| Lilly USA, LLCMounjaro, Trulicity | $151 | $95,98480 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere, Bevespi Aerosphere | $563 | $64,510134 claims |
| AbbVieUbrelvy, Linzess | $832 | $41,34041 claims |
| MerckJanuvia | $91 | $24,09625 claims |
| PfizerEliquis | $180 | $20,83121 claims |
| Astellas Pharma US IncMyrbetriq | $232 | $11,39220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,610 family providers in Louisiana.
Other family in Thibodaux
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.